Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VIVO Cannabis Inc. V.PDA


Primary Symbol: VVCIF

VIVO Cannabis Inc is a Canada-based company. It is involved in the production and sale of medical and recreational cannabis and the provision of cannabis-related medical information and services in Canada. The company's operating segment includes Cannabis, Patient Clinics, and Corporate. It generates maximum revenue from the Cannabis segment. The company has a presence across three geographical locations - Canada, Germany, and Australia.


OTCQB:VVCIF - Post by User

Bullboard Posts
Post by Goalkeeper1on Mar 06, 2018 1:22pm
152 Views
Post# 27669094

abcann update

abcann update
March 6, 2018 at 7:27 am
ABcann Details International Expansion Plans in Corporate Update
Published by NCV Newswire
Visit the ABcann Global Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.


ABcann Global Provides Business Update
NAPANEE, Ontario, March 06, 2018 (GLOBE NEWSWIRE) — ABcann Global Corporation (TSXV:ABCN) (“ABcann” or the “Company”) is pleased to provide the following business update.

Over the past five months we have enhanced our leadership team, strengthened our balance sheet, improved operational effectiveness and executed a strategic acquisition.  Last week, after completing an extensive strategic review of our operations and growth plans, our board of directors approved our 2018 Business Plan, and the ABcann team is now sharply focused on execution.

Barry Fishman, Chief Executive Officer
With the closing of our recent oversubscribed financing of $75 million, the Company is well-positioned with over $135 million in cash to accelerate the growth of our business. A disciplined capital allocation process is in place, with the following four priorities:

Expanding to 500,000 square feet to produce over 30,000 kilograms of capacity
Focusing on branding and product innovation in the medical and adult-use sectors
Expanding our proven Harvest Medicine platform to multiple new locations in 2018; and
Developing strategic partnerships in the industry to broaden our reach and scale
ABcann is widely recognized as a producer of premium cannabis – grown using proprietary advanced techniques tailored to optimize quality and consistency. High-tech growing is our current differentiator. Our technology allows us to precisely control environmental variables to maximize yield and produce pharmaceutical-grade cannabis.

“In mid-2018 we are excited to roll-out a complete corporate and product line rebrand to better match our strategic vision and desired product positioning in both the medical and adult-use markets. More details will follow in an upcoming release,” said Mr. Fishman.”

The Company continues to pursue international opportunities and aims to obtain a distribution license for Germany after GMP certification of its Vanluven facility and required stability testing is completed. The Company is expecting to begin exporting cannabis to Australia mid-year, and to Germany close to year-end, and continues to assess opportunities in other international markets.

About ABcann:

ABcann holds production and sales licenses from Health Canada. Its flagship facility in Napanee, Ontario contains proprietary plant-growing technology, centred on its specially designed, environmentally-controlled growing chambers. This approach results in the production of pharmaceutical-grade cannabis products.

The Company is expanding its production capacity and pursuing partnership and product development opportunities domestically, as well as in select international markets, such as Germany, Australia and Israel.

An updated Investor Presentation is available on our website at the following link:

https://www.abcannglobal.com/assets/Investor_Presentation_March_2018.pdf

Original Press Release

The most reliable, fact-based information on ABcann Global found only on its Investor Dashboard.

Before this cannabis stock news is here, it’s published to subscribers on 420 Investor.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. For questions contact us.
 

Get Our Sunday Newsletter

email address

IN THIS ARTICLE:
ABCANN, ABCCF, ABCN, ACMPR, CANADA
RELATED NEWS:
Organigram Boosts Annual Production Capacity Outlook as Yields Exceed 400 Grams per Square Foot
Emerald Farms BC Cannabis JV Receives Health Canada License for 1.1 Million Square Foot Facility
Cannabis Wheaton Streaming Deal with FV Pharma Projected to Yield 200 Million Grams Annually
Canopy Growth to Offer Creative Tweed Branding Event to Fashion Community
 

Cheers
Gk1

Bullboard Posts